标题
Translating JAKs to Jakinibs
作者
关键词
-
出版物
JOURNAL OF IMMUNOLOGY
Volume 204, Issue 8, Pages 2011-2020
出版商
The American Association of Immunologists
发表日期
2020-04-07
DOI
10.4049/jimmunol.1901477
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- JAK Inhibitor Therapy in a Child with Inherited USP18 Deficiency
- (2020) Fahad Alsohime et al. NEW ENGLAND JOURNAL OF MEDICINE
- Assessment of Clinical Response to Janus Kinase Inhibition in Patients With Familial Chilblain Lupus and TREX1 Mutation
- (2019) Nick Zimmermann et al. JAMA Dermatology
- Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies
- (2019) Andres Forero-Torres et al. BLOOD
- PF-06651600, a dual JAK3/TEC family kinase inhibitor
- (2019) Hua Xu et al. ACS Chemical Biology
- Identification of rare coding variants in TYK2 protective for rheumatoid arthritis in the Japanese population and their effects on cytokine signalling
- (2019) Tomoki Motegi et al. ANNALS OF THE RHEUMATIC DISEASES
- Targeting Interleukin-6 Signaling in Clinic
- (2019) Sujin Kang et al. IMMUNITY
- Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study
- (2019) Josef S Smolen et al. LANCET
- Homozygosity for TYK2 P1104A underlies tuberculosis in about 1% of patients in a cohort of European ancestry
- (2019) Gaspard Kerner et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis
- (2019) Katie Bechman et al. RHEUMATOLOGY
- Tofacitinib for the treatment of recalcitrant palmoplantar pustulosis: A case report
- (2019) Dylan Haynes et al. AUSTRALASIAN JOURNAL OF DERMATOLOGY
- Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy
- (2019) Mark C. Genovese et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Oral JAK/SYK-inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in atopic dermatitis
- (2019) Ana B. Pavel et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Tofacitinib in Amyopathic Dermatomyositis–Associated Interstitial Lung Disease
- (2019) Zhiwei Chen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain
- (2019) James R. Burke et al. Science Translational Medicine
- Live Zoster Vaccine in Patients with Rheumatoid Arthritis Treated with Tofacitinib with or without Methotrexate, or Adalimumab with Methotrexate
- (2019) Leonard H Calabrese et al. ARTHRITIS CARE & RESEARCH
- Upadacitinib versus Placebo or Adalimumab in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase 3, Double‐Blind, Randomized Controlled Trial
- (2019) Roy Fleischmann et al. Arthritis & Rheumatology
- Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial
- (2019) Peter C. Taylor et al. Journal of Clinical Medicine
- Recurrent somatic JAK3 mutations in NK-cell enteropathy
- (2019) Wenbin Xiao et al. BLOOD
- Efficacy and safety of topical delgocitinib in patients with chronic hand eczema: data from a randomised, double‐blind, vehicle‐controlled Phase 2a study
- (2019) M. Worm et al. BRITISH JOURNAL OF DERMATOLOGY
- Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade
- (2019) Joseph L. Benci et al. CELL
- Phase 2 clinical study of delgocitinib ointment in pediatric patients with atopic dermatitis
- (2019) Hidemi Nakagawa et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis
- (2019) Melinda J. Gooderham et al. JAMA Dermatology
- Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma
- (2018) Tycel J. Phillips et al. BLOOD
- Efficacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: a phase II, multicentre, randomized, vehicle-controlled clinical study
- (2018) H. Nakagawa et al. BRITISH JOURNAL OF DERMATOLOGY
- Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study
- (2018) G.J. Schmieder et al. BRITISH JOURNAL OF DERMATOLOGY
- Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH trials
- (2018) Madan Jagasia et al. Immunotherapy
- JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies
- (2018) Gina A. Montealegre Sanchez et al. JOURNAL OF CLINICAL INVESTIGATION
- Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study
- (2018) Bruce E Sands et al. Journal of Crohns & Colitis
- Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study
- (2018) Emma Guttman-Yassky et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients
- (2018) Lucy Y. Liu et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- T-cell–mediated immune response to pneumococcal conjugate vaccine (PCV-13) and tetanus toxoid vaccine in patients with moderate-to-severe psoriasis during tofacitinib treatment
- (2018) Kevin L. Winthrop et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial
- (2018) Daniel J Wallace et al. LANCET
- Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms
- (2018) J. Berdeja et al. LEUKEMIA RESEARCH
- Tofacitinib is associated with attainment of the minimally important reduction in axial magnetic resonance imaging inflammation in ankylosing spondylitis patients
- (2018) Walter P Maksymowych et al. RHEUMATOLOGY
- The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis
- (2018) Douglas J Veale et al. RHEUMATOLOGY
- Momelotinib therapy for myelofibrosis: a 7-year follow-up
- (2018) Ayalew Tefferi et al. Blood Cancer Journal
- The psoriasis-protective TYK2 I684S variant impairs IL-12 stimulated pSTAT4 response in skin-homing CD4+ and CD8+ memory T-cells
- (2018) C. Enerbäck et al. Scientific Reports
- Mechanistic Insights into Regulation of JAK2 Tyrosine Kinase
- (2018) Stevan R. Hubbard Frontiers in Endocrinology
- Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis
- (2018) Kim Papp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Characterization and changes of lymphocyte subsets in baricitinib-treated patients with rheumatoid arthritis: an integrated analysis
- (2018) Yoshiya Tanaka et al. Arthritis & Rheumatology
- Diagnosis and Management of Rheumatoid Arthritis
- (2018) Daniel Aletaha et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial
- (2018) Désirée van der Heijde et al. LANCET
- Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial
- (2018) Philip Mease et al. LANCET
- Lung-restricted inhibition of Janus kinase 1 is effective in rodent models of asthma
- (2018) Hart S. Dengler et al. Science Translational Medicine
- Tofacitinib relieves symptoms of stimulator of interferon genes (STING)–associated vasculopathy with onset in infancy caused by 2 de novo variants in TMEM173
- (2017) Jieun Seo et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- JAK1 gain-of-function causes an autosomal dominant immune dysregulatory and hypereosinophilic syndrome
- (2017) Kate L. Del Bel et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans
- (2017) Atli Thorarensen et al. JOURNAL OF MEDICINAL CHEMISTRY
- Fatal ruxolitinib-related JC virus meningitis
- (2017) Begoña Ballesta et al. JOURNAL OF NEUROVIROLOGY
- Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure
- (2017) Lucy Y. Liu et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Jak3 deficiency blocks innate lymphoid cell development
- (2017) M L Robinette et al. Mucosal Immunology
- Managing rheumatic and musculoskeletal diseases — past, present and future
- (2017) Gerd R. Burmester et al. Nature Reviews Rheumatology
- Tofacitinib improves atherosclerosis despite up-regulating serum cholesterol in patients with active rheumatoid arthritis: a cohort study
- (2017) Kensuke Kume et al. RHEUMATOLOGY INTERNATIONAL
- Tofacitinib rapidly ameliorated polyarthropathy in a patient with systemic sclerosis
- (2017) T Komai et al. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
- Genome-Wide Association Meta-Analysis Reveals Novel Juvenile Idiopathic Arthritis Susceptibility Loci
- (2017) Laura A. McIntosh et al. Arthritis & Rheumatology
- The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial
- (2017) Kevin L. Winthrop et al. Arthritis & Rheumatology
- Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy
- (2017) Kevin L. Winthrop et al. Arthritis & Rheumatology
- Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study
- (2017) Claire N Harrison et al. Lancet Haematology
- Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON)
- (2016) Josef S Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis
- (2016) Jeffrey R Curtis et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy of VX-509 (decernotinib) in combination with a disease-modifying antirheumatic drug in patients with rheumatoid arthritis: clinical and MRI findings
- (2016) Mark C Genovese et al. ANNALS OF THE RHEUMATIC DISEASES
- A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis
- (2016) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial
- (2016) R. Bissonnette et al. BRITISH JOURNAL OF DERMATOLOGY
- Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
- (2016) Joseph L. Benci et al. CELL
- The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia
- (2016) Matthew D. Blunt et al. CLINICAL CANCER RESEARCH
- A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis
- (2016) Vikas Gupta et al. HAEMATOLOGICA
- Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173 -activating mutations in 3 children
- (2016) Marie-Louise Frémond et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity
- (2016) C. A. Dendrou et al. Science Translational Medicine
- Biallelic JAK1 mutations in immunodeficient patient with mycobacterial infection
- (2016) Davide Eletto et al. Nature Communications
- Trisomy 21 consistently activates the interferon response
- (2016) Kelly D Sullivan et al. eLife
- A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis
- (2016) Vikas Gupta et al. HAEMATOLOGICA
- Molecular mechanisms of pruritus
- (2016) J. Meng et al. Current Research in Translational Medicine
- SP0027 One for All – Patient Research Partners Involved in Disseminating Eular Recommendations Among Belgium Patients
- (2015) I. De Keyser ANNALS OF THE RHEUMATIC DISEASES
- The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours
- (2015) S J Thomas et al. BRITISH JOURNAL OF CANCER
- Super-enhancers delineate disease-associated regulatory nodes in T cells
- (2015) Golnaz Vahedi et al. NATURE
- Preliminary response to Janus kinase inhibition with baricitinib in chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperatures (CANDLE)
- (2015) G Montealegre et al. Pediatric Rheumatology
- Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial
- (2015) Joel M Kremer et al. ARTHRITIS RESEARCH & THERAPY
- Editorial: Decernotinib: A Next-Generation Jakinib
- (2015) Massimo Gadina et al. Arthritis & Rheumatology
- A Randomized, Double-Blind, Placebo-Controlled, Twelve-Week, Dose-Ranging Study of Decernotinib, an Oral Selective JAK-3 Inhibitor, as Monotherapy in Patients With Active Rheumatoid Arthritis
- (2015) Roy M. Fleischmann et al. Arthritis & Rheumatology
- VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis
- (2015) Mark C. Genovese et al. Arthritis & Rheumatology
- Potential Mechanisms Leading to the Abnormal Lipid Profile in Patients With Rheumatoid Arthritis Versus Healthy Volunteers and Reversal by Tofacitinib
- (2015) Christina Charles-Schoeman et al. Arthritis & Rheumatology
- An Evaluation of Risk Factors for Major Adverse Cardiovascular Events During Tocilizumab Therapy
- (2015) Vijay U. Rao et al. Arthritis & Rheumatology
- Pharmacologic inhibition of JAK-STAT signaling promotes hair growth
- (2015) S. Harel et al. Science Advances
- Genetic studies reveal an unexpected negative regulatory role for Jak2 in thrombopoiesis
- (2014) S. C. Meyer et al. BLOOD
- In Search of Magic Bullets: The Golden Age of Immunotherapeutics
- (2014) John J. O’Shea et al. CELL
- Selective JAK inhibitors in development for rheumatoid arthritis
- (2014) Peter Norman EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Intravenous golimumab in rheumatoid arthritis
- (2014) Marc D Cohen et al. Expert Review of Clinical Immunology
- Anti-TNF therapy: past, present and future
- (2014) C. Monaco et al. INTERNATIONAL IMMUNOLOGY
- Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
- (2014) Luzhou Xing et al. NATURE MEDICINE
- Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis
- (2014) Kevin L. Winthrop et al. Arthritis & Rheumatology
- Longterm Safety and Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis: A Cumulative Analysis of Up to 4.6 Years of Exposure
- (2013) M. C. Genovese et al. JOURNAL OF RHEUMATOLOGY
- Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial
- (2013) Cem Gabay et al. LANCET
- Conditional Deletion of Jak2 Reveals an Essential Role in Hematopoiesis throughout Mouse Ontogeny: Implications for Jak2 Inhibition in Humans
- (2013) Sung O. Park et al. PLoS One
- Meta-analysis of TYK2 gene polymorphisms association with susceptibility to autoimmune and inflammatory diseases
- (2010) Jin-Hui Tao et al. MOLECULAR BIOLOGY REPORTS
- Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study
- (2008) Mark C. Genovese et al. ARTHRITIS AND RHEUMATISM
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More